Your test, explained
5 min readInsulin-like Growth Factor 1 (IGF-1) Blood Test: The Growth Hormone Surrogate
A precise quantitative measurement of serum Insulin-like Growth Factor 1. It serves as the definitive, stable biomarker for evaluating pituitary Growth Hormone (GH) output, diagnosing acromegaly, and tracking systemic anabolic capacity.
Your options, side by side
Compare retailer prices.
Find a listing that fits your needs. Review the details, then order with the retailer.
No retailer listings yet.
Read the test guide or explore other tests in the directory.
Explore testsPrices shown are listed test prices, not checkout totals. Expand a listing for supplied fees and its observation date. Check included measurements, collection requirements, and the performing lab before ordering.
Understand before you decide
The test, explained.
Overview
Trying to measure Growth Hormone (GH) directly with a standard blood test is clinically futile. GH is secreted in rapid, unpredictable pulses, mostly while you sleep. To understand your true anabolic capacity, we must measure the stable byproduct: IGF-1.
As a senior clinical endocrinologist, I utilize the Insulin-like Growth Factor 1 (IGF-1) test as the definitive "moving average" of your pituitary gland's output. When your pituitary releases Growth Hormone, it travels directly to your liver, which responds by synthesizing IGF-1. Unlike GH, which vanishes from the blood in minutes, IGF-1 is bound to specific carrier proteins (IGFBPs) that give it a highly stable half-life of 15 to 24 hours. Therefore, a single, fasting measurement of IGF-1 provides a highly accurate reflection of your systemic anabolic tone, cellular repair capacity, and total daily Growth Hormone secretion. It is the indispensable biomarker for diagnosing both catastrophic excess (Acromegaly) and silent deficiencies.
About this test
Advanced Clinical Diagnostic Utility of IGF-1
To extract genuine clinical utility from this endocrine marker, one must understand how the liver translates pituitary signals into systemic cellular growth.
1. The AGHD (Adult Growth Hormone Deficiency) Paradigm
The Silent Decline: While pediatric GH deficiency results in short stature, Adult Growth Hormone Deficiency (AGHD) presents as a insidious metabolic collapse. Patients suffer from severe central adiposity (visceral fat gain), profound loss of lean muscle mass, osteopenia, and a distinct lack of psychological vitality. A severely depressed IGF-1 level, adjusted for age, is the primary gating biomarker to authorize definitive GH stimulation testing and subsequent hormone replacement therapy.
2. Acromegaly and Somatotroph Adenomas
The Runaway Train: If a benign tumor develops on the pituitary gland (a somatotroph adenoma), it will pump out excessive GH, driving IGF-1 to astronomical levels. In adults, because the growth plates of the bones have fused, this excess IGF-1 causes the soft tissues and internal organs to grow uncontrollably—a condition known as Acromegaly. Symptoms include a widening jaw, expanding ring and shoe sizes, severe sleep apnea, and cardiomegaly. IGF-1 is the only reliable screening tool to catch this early.
3. The Hepatic and Nutritional Biosensor
The Famine Response: IGF-1 is not purely driven by the pituitary; it is exquisitely sensitive to your nutritional status. The liver requires adequate protein and insulin to synthesize IGF-1. In states of anorexia, severe caloric restriction, or uncontrolled Type 1 Diabetes, the liver becomes resistant to Growth Hormone, and IGF-1 levels plummet. This evolutionary mechanism prevents the body from growing during a famine.
When to discuss this test
You should prioritize this targeted endocrine evaluation when:
- You are experiencing the classic symptoms of Adult Growth Hormone Deficiency (AGHD): unexplained loss of muscle mass, increasing visceral belly fat, thinning skin, and a profound, unyielding sense of fatigue.
- You notice physical changes indicative of Acromegaly, such as having to resize your rings, an expanding jawline, widening gaps between your teeth, or unexplained joint pain and excessive sweating.
- You have a known history of traumatic brain injury (TBI) or prior pituitary tumors, which frequently result in secondary hypopituitarism and GH deficiency.
- You are currently undergoing prescribed Growth Hormone (Somatropin) or secretagogue (e.g., Ipamorelin) replacement therapy and require precise titration to remain within the optimal, age-adjusted physiological range.
Who may benefit
This test is an absolute necessity for endocrinologists diagnosing pituitary adenomas, longevity and anti-aging specialists tracking anabolic cellular decline, and pediatricians evaluating children who are consistently falling off their growth curve percentiles.
How this test is used
- Adult Growth Hormone Deficiency (AGHD)
- Acromegaly and Gigantism
- Pituitary Adenomas (Somatotropinomas)
- Severe Malnutrition or Anorexia Nervosa
Before your appointment
Plan your visit.
- Fasting
- Required · 10 hours
- Collection timing
- Morning collection preferred
How to prepare
- Strict Fasting (10-12 Hours): While some low-tier commercial labs suggest fasting is unnecessary, this is a fundamental clinical error. Hepatic IGF-1 synthesis is heavily modulated by acute insulin and portal amino acid concentrations. Eating a high-protein or high-carbohydrate meal will transiently alter IGF-Binding Proteins (specifically IGFBP-1), which can distort the measurement of total IGF-1. A 10-12 hour water-only fast ensures a pristine physiological baseline.
- Disclose Estrogen Therapy: You must explicitly inform your physician if you are taking oral estrogens (birth control pills or oral HRT). The 'first-pass' metabolism of oral estrogen through the liver aggressively suppresses hepatic IGF-1 synthesis. A woman on oral estrogen may have a falsely low IGF-1 level despite having a perfectly healthy pituitary gland.
- Avoid Acute Physical Trauma: Do not test immediately following severe physical trauma or extreme endurance exercise (e.g., running a marathon), as extreme acute catabolic stress temporarily suppresses IGF-1 output.
Important considerations
The Age-Adjusted Reference Trap: IGF-1 levels peak during puberty and undergo a massive, natural decline as we age (somatopause). An IGF-1 level of 150 ng/mL would be considered pathologically low for a 20-year-old, but perfectly normal for a 65-year-old. Always ensure your lab results are strictly interpreted against age- and sex-matched normative data, not just a generic "adult" reference range.
Follow the instructions from your retailer and clinician. Information on this page is educational and does not replace individual medical advice.
See what to expect
Sample reports & resources.
Published examples and supporting files for this test.
No sample files are published for this test yet.
Looking for your own results? Open your reports dashboard
For a closer look
Sources & further reading.
Further reading
Recent Clinical Breakthroughs (2025-2026):
- IGF-1 and Cognitive Frailty: A landmark 2025 longitudinal study published in The Lancet Neurology established a definitive link between low-quartile serum IGF-1 levels and the rapid acceleration of age-related sarcopenia and cognitive decline. The study demonstrated that maintaining IGF-1 in the upper 50th percentile for a patient's age group significantly preserves hippocampal volume and muscle fiber density.
- Revising Oral HRT Guidelines: 2026 clinical endocrinology guidelines now heavily discourage the use of oral estrogens in postmenopausal women with borderline AGHD. Advanced metabolic tracking proved that switching these patients from oral estradiol to transdermal estradiol (patches) bypassed hepatic suppression, naturally restoring IGF-1 levels by up to 40% without the need for exogenous growth hormone.
- IGF-1 as a Neoplastic Biosensor: Breakthrough 2025 oncology research in Cancer Epidemiology, Biomarkers & Prevention highlighted the delicate balance of IGF-1 optimization. While low IGF-1 drives frailty, driving IGF-1 supra-physiologically high (often seen in unsupervised anti-aging clinics) acts as a powerful mitogen, significantly increasing the risk of prostate and breast tissue neoplasia. Precision titration is now mandatory.
Sources
- The Lancet Neurology (2025). "Serum Insulin-like Growth Factor-1 Trajectories as Predictive Biomarkers for Sarcopenia and Cognitive Frailty in Aging Populations."
- Journal of Clinical Endocrinology & Metabolism (2026). "Hepatic First-Pass Estrogen Metabolism and the Iatrogenic Suppression of IGF-1: The Case for Transdermal HRT."
- Cancer Epidemiology, Biomarkers & Prevention (2025). "The Mitogenic Risk of Supra-Physiological IGF-1 Optimization in Anti-Aging Protocols."
